TELA Bio
TELA Bio's revenue rose 15.8% to $80 million in fiscal 2025. Its operating margin was −42.0%, up from −49.2% a year earlier. Free cash flow was −$29 million. The diluted share count rose 64.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
TELA Bio lost money in fiscal 2025: a net loss of $39 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 44 | 42 | 47 | 53 | 51 |
| Debt incl. finance leases | 32 | 40 | 40 | 41 | 56 |
| Net debt (negative means net cash) | −12 | −2 | −6 | −12 | 5 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 1.6x | 2.8x | 2.1x | 1.4x | 8.8x |
| Interest coverage | −8.2x | −9.6x | −8.4x | −6.5x | −6.4x |
| Current ratio | 5.6x | 5.0x | 4.2x | 5.0x | 4.2x |
| Quick ratio | 4.9x | 4.1x | 3.5x | 4.2x | 3.6x |
Cash flow
Projections
Project TELA Bio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $186,250 of TELA Bio shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Joseph H CapperDirector | Bought | 25,000 | $1.22 | $30,500 | Form 4 |
| Sep 16, 2026 | Joseph H CapperDirector | Bought | 50,000 | $1.17 | $58,500 | Form 4 |
| Sep 15, 2026 | Joseph H CapperDirector | Bought | 50,000 | $1.06 | $53,000 | Form 4 |
| Sep 14, 2026 | Joseph H CapperDirector | Bought | 25,000 | $1.02 | $25,500 | Form 4 |
| Aug 17, 2026 | Heather C GetzChief Executive Officer, Director | Bought | 12,500 | $0.66 | $8,250 | Form 4 |
| Aug 14, 2026 | Heather C GetzChief Executive Officer, Director | Bought | 15,000 | $0.70 | $10,500 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 4 of 9 | 4 of 9 |
| Rule of 40 | −29.8% | −42.9% | −19.9% |
| Altman Z'' | −12.26 | −10.91 | −13.97 |
| Accruals ratio | −8.0% | 4.6% | −12.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 5 of 9 | 4 of 9 | 4 of 9 |
Compare
Put TELA Bio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| TELA Bio | FY25 | 15.8% | −42.0% | −35.7% | −190.2% | — | 4 | |
| Pro Dex | FY26 | 16.4% | 16.8% | 8.7% | 19.6% | 0.6x | 7 | Compare |
| Sight Sciences | FY25 | −3.1% | −48.0% | −38.7% | — | — | 5 | Compare |
| IRADIMED | FY25 | 14.4% | 31.2% | 20.5% | — | — | — | Compare |
| Delcath Systems | FY25 | 129.1% | 0.8% | 24.6% | 2.8% | −101.4x | 6 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 4 | 8 | 15 | 18 | 30 | 41 | 58 | 69 | 80 |
| Revenue growth | — | 94.9% | 86.7% | 17.9% | 61.8% | 40.6% | 41.1% | 18.6% | 15.8% |
| Gross profit | 2 | 3 | 9 | 11 | 19 | 27 | 40 | 46 | 54 |
| Research and development | 6 | 4 | 4 | 4 | 7 | 9 | 10 | 9 | 9 |
| Operating income | −17 | −18 | −19 | −25 | −30 | −39 | −44 | −34 | −34 |
| Net income | −21 | −21 | −22 | −29 | −33 | −44 | −47 | −38 | −39 |
| Diluted EPS (US$) | — | −101.41 | −17.10 | −2.23 | −2.30 | −2.72 | −2.04 | −1.33 | −0.83 |
| Diluted shares (millions) | 0 | 0 | 2 | 13 | 14 | 16 | 23 | 28 | 47 |
| Cash flow | |||||||||
| Cash from operations | −16 | −20 | −26 | −24 | −30 | −41 | −41 | −42 | −28 |
| Capital expenditure | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Free cash flow | −16 | −20 | −26 | −25 | −31 | −42 | −41 | −43 | −29 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 0 | 2 | 4 | 4 | 5 | 4 | 4 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 11 | 17 | 55 | 74 | 44 | 42 | 47 | 53 | 51 |
| Debt incl. finance leases | — | — | 30 | 31 | 32 | 40 | 40 | 41 | 56 |
| Total assets | — | 27 | 68 | 86 | 62 | 68 | 78 | 87 | 81 |
| Total liabilities | — | 41 | 37 | 37 | 42 | 54 | 59 | 58 | 75 |
| Shareholders' equity | −108 | −138 | 31 | 49 | 20 | 14 | 19 | 28 | 6 |
| Margins and ratios | |||||||||
| Gross margin | 59.6% | 35.6% | 60.0% | 61.7% | 63.9% | 65.3% | 68.6% | 67.1% | 67.7% |
| Operating margin | −398.7% | −214.9% | −124.1% | −138.8% | −100.0% | −94.2% | −75.4% | −49.2% | −42.0% |
| Net margin | −502.6% | −254.9% | −145.2% | −158.1% | −112.9% | −107.0% | −79.8% | −54.6% | −48.4% |
| Free cash flow margin | −388.3% | −241.6% | −166.5% | −135.2% | −105.4% | −100.5% | −70.9% | −61.5% | −35.7% |
| Rule of 40 (growth + FCF margin) | — | −146.6% | −79.8% | −117.3% | −43.6% | −59.9% | −29.8% | −42.9% | −19.9% |
| Return on capital | — | — | — | — | — | −310.3% | −280.0% | −182.2% | −190.2% |
| Return on equity | — | — | — | −72.0% | −96.3% | −257.5% | −281.2% | −159.9% | −223.3% |
| Return on assets | — | — | −47.1% | −37.3% | −44.7% | −67.9% | −64.0% | −46.0% | −46.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |